Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin.

Galaine J, Turco C, Vauchy C, Royer B, Mercier-Letondal P, Queiroz L, Loyon R, Mouget V, Boidot R, Laheurte C, Lakkis Z, Jary M, Adotévi O, Borg C, Godet Y.

Int J Cancer. 2019 Dec 1;145(11):3112-3125. doi: 10.1002/ijc.32620. Epub 2019 Aug 31.

PMID:
31396953
2.

Circulating NKp46+ Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer.

Picard E, Godet Y, Laheurte C, Dosset M, Galaine J, Beziaud L, Loyon R, Boullerot L, Lauret Marie Joseph E, Spehner L, Jacquin M, Eberst G, Gaugler B, Le Pimpec-Barthes F, Fabre E, Westeel V, Caignard A, Borg C, Adotévi O.

Oncoimmunology. 2018 Oct 19;8(2):e1527498. doi: 10.1080/2162402X.2018.1527498. eCollection 2019.

3.

Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment.

Vrecko S, Guenat D, Mercier-Letondal P, Faucheu H, Dosset M, Royer B, Galaine J, Boidot R, Kim S, Jary M, Adotévi O, Borg C, Godet Y.

Oncotarget. 2018 Oct 23;9(83):35394-35407. doi: 10.18632/oncotarget.26247. eCollection 2018 Oct 23.

4.

Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.

Mercier-Letondal P, Marton C, Deschamps M, Ferrand C, Vauchy C, Chenut C, Baguet A, Adotévi O, Borg C, Galaine J, Godet Y.

Hum Gene Ther. 2018 Oct;29(10):1202-1212. doi: 10.1089/hum.2018.091.

PMID:
30136612
5.

In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial.

Adotevi O, Godet Y, Galaine J, Lakkis Z, Idirene I, Certoux JM, Jary M, Loyon R, Laheurte C, Kim S, Dormoy A, Pouthier F, Barisien C, Fein F, Tiberghien P, Pivot X, Valmary-Degano S, Ferrand C, Morel P, Delabrousse E, Borg C.

Oncoimmunology. 2018 Mar 19;7(5):e1424673. doi: 10.1080/2162402X.2018.1424673. eCollection 2018.

6.

PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma.

Asgarova A, Asgarov K, Godet Y, Peixoto P, Nadaradjane A, Boyer-Guittaut M, Galaine J, Guenat D, Mougey V, Perrard J, Pallandre JR, Bouard A, Balland J, Tirole C, Adotevi O, Hendrick E, Herfs M, Cartron PF, Borg C, Hervouet E.

Oncoimmunology. 2018 Feb 1;7(5):e1423170. doi: 10.1080/2162402X.2017.1423170. eCollection 2018.

7.

SALL4 oncogene is an immunogenic antigen presented in various HLA-DR contexts.

Kroemer M, Spehner L, Mercier-Letondal P, Boullerot L, Kim S, Jary M, Galaine J, Picard E, Ferrand C, Nguyen T, Larosa F, Adotévi O, Godet Y, Borg C.

Oncoimmunology. 2018 Jan 17;7(4):e1412030. doi: 10.1080/2162402X.2017.1412030. eCollection 2018.

8.

Echinococcus multilocularis vesicular fluid inhibits activation and proliferation of natural killer cells.

Bellanger AP, Mougey V, Pallandre JR, Gbaguidi-Haore H, Godet Y, Millon L.

Folia Parasitol (Praha). 2017 Aug 25;64. pii: 2017.029. doi: 10.14411/fp.2017.029.

9.

Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice.

Rangan L, Galaine J, Boidot R, Hamieh M, Dosset M, Francoual J, Beziaud L, Pallandre JR, Lauret Marie Joseph E, Asgarova A, Borg C, Al Saati T, Godet Y, Latouche JB, Valmary-Degano S, Adotévi O.

Oncotarget. 2017 Jul 25;8(30):48959-48971. doi: 10.18632/oncotarget.16900.

10.

Pour comprendre : l’activation lymphocytaire T.

Galaine J, Godet Y, Adotévi O.

Bull Cancer. 2016 Nov;103 Suppl 1:S127-S131. doi: 10.1016/S0007-4551(16)30369-1. French.

PMID:
28057175
11.

Fungal peptides from pneumonitis hypersensitivity etiologic agents are able to induce specific cellular immune response.

Bellanger AP, Lignon T, Godet Y, Rognon B, Reboux G, Gbaguidi-Haore H, Borg C, Millon L.

J Immunol Methods. 2017 Jan;440:67-73. doi: 10.1016/j.jim.2016.11.009. Epub 2016 Nov 20.

PMID:
27876506
12.

Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells.

Galaine J, Kellermann G, Guillaume Y, Boidot R, Picard E, Loyon R, Queiroz L, Boullerot L, Beziaud L, Jary M, Mansi L, André C, Lethier L, Ségal-Bendirdjian E, Borg C, Godet Y, Adotévi O.

J Immunol. 2016 Sep 1;197(5):1597-608. doi: 10.4049/jimmunol.1502633. Epub 2016 Aug 1.

13.

Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score.

Jary M, Lecomte T, Bouché O, Kim S, Dobi E, Queiroz L, Ghiringhelli F, Etienne H, Léger J, Godet Y, Balland J, Lakkis Z, Adotevi O, Bonnetain F, Borg C, Vernerey D.

Int J Cancer. 2016 Nov 15;139(10):2325-35. doi: 10.1002/ijc.30367. Epub 2016 Aug 13.

14.

Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.

Laheurte C, Galaine J, Beziaud L, Dosset M, Kerzerho J, Jacquemard C, Gaugler B, Ferrand C, Dormoy A, Aubin F, Jacoulet P, Westeel V, Borg C, Tartour E, Godet Y, Maillère B, Adotévi O.

Oncoimmunology. 2016 Feb 18;5(5):e1137416. doi: 10.1080/2162402X.2015.1137416. eCollection 2016 May.

15.

IL-21-Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent Manner.

Loyon R, Picard E, Mauvais O, Queiroz L, Mougey V, Pallandre JR, Galaine J, Mercier-Letondal P, Kellerman G, Chaput N, Wijdenes J, Adotévi O, Ferrand C, Romero P, Godet Y, Borg C.

J Immunol. 2016 Jul 1;197(1):85-96. doi: 10.4049/jimmunol.1501147. Epub 2016 May 27.

16.

Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity.

Beziaud L, Mansi L, Ravel P, Marie-Joseph EL, Laheurte C, Rangan L, Bonnefoy F, Pallandre JR, Boullerot L, Gamonet C, Vrecko S, Queiroz L, Maurina T, Mouillet G, Hon TN, Curtit E, Royer B, Gaugler B, Bayry J, Tartour E, Thiery-Vuillemin A, Pivot X, Borg C, Godet Y, Adotévi O.

Cancer Res. 2016 Jul 15;76(14):4100-12. doi: 10.1158/0008-5472.CAN-15-2452. Epub 2016 May 17.

17.

Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine.

Galaine J, Borg C, Godet Y, Adotévi O.

Vaccines (Basel). 2015 Jun 30;3(3):490-502. doi: 10.3390/vaccines3030490. Review.

18.

Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma.

Jary M, Vernerey D, Lecomte T, Dobi E, Ghiringhelli F, Monnien F, Godet Y, Kim S, Bouché O, Fratte S, Gonçalves A, Leger J, Queiroz L, Adotevi O, Bonnetain F, Borg C.

Cancer Epidemiol Biomarkers Prev. 2015 Mar;24(3):603-12. doi: 10.1158/1055-9965.EPI-14-1059. Epub 2015 Jan 12.

19.

Erratum to: New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies.

Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, Godet Y, Ysebaert L, Tournilhac O, Dartigeas C, Larosa F, Deconinck E, Saas P, Borg C, Deschamps M, Ferrand C.

Exp Hematol Oncol. 2016 Apr 14;5:10. doi: 10.1186/s40164-016-0038-1. eCollection 2015.

20.

New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies.

Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, Godet Y, Ysebaert L, Tournilhac O, Caroline D, Larosa F, Deconinck E, Saas P, Borg C, Deschamps M, Ferrand C.

Exp Hematol Oncol. 2016 Mar 1;5:7. doi: 10.1186/s40164-016-0036-3. eCollection 2015. Erratum in: Exp Hematol Oncol. 2015;5:10.

21.

CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes.

Vauchy C, Gamonet C, Ferrand C, Daguindau E, Galaine J, Beziaud L, Chauchet A, Henry Dunand CJ, Deschamps M, Rohrlich PS, Borg C, Adotevi O, Godet Y.

Int J Cancer. 2015 Jul 1;137(1):116-26. doi: 10.1002/ijc.29366. Epub 2014 Dec 12.

22.

Immunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccine.

Seyed N, Taheri T, Vauchy C, Dosset M, Godet Y, Eslamifar A, Sharifi I, Adotevi O, Borg C, Rohrlich PS, Rafati S.

PLoS One. 2014 Oct 13;9(10):e108848. doi: 10.1371/journal.pone.0108848. eCollection 2014.

23.

Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination.

Dosset M, Vauchy C, Beziaud L, Adotevi O, Godet Y.

Oncoimmunology. 2013 Mar 1;2(3):e23430.

24.

Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine.

Adotévi O, Dosset M, Galaine J, Beziaud L, Godet Y, Borg C.

Hum Vaccin Immunother. 2013 May;9(5):1073-7. doi: 10.4161/hv.23587. Epub 2013 Jan 28. Review.

25.
26.

Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.

Dobi E, Monnien F, Kim S, Ivanaj A, N'Guyen T, Demarchi M, Adotevi O, Thierry-Vuillemin A, Jary M, Kantelip B, Pivot X, Godet Y, Degano SV, Borg C.

Clin Colorectal Cancer. 2013 Mar;12(1):28-36. doi: 10.1016/j.clcc.2012.09.002. Epub 2012 Oct 17.

PMID:
23083634
27.

Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor.

Dosset M, Godet Y, Vauchy C, Beziaud L, Lone YC, Sedlik C, Liard C, Levionnois E, Clerc B, Sandoval F, Daguindau E, Wain-Hobson S, Tartour E, Langlade-Demoyen P, Borg C, Adotévi O.

Clin Cancer Res. 2012 Nov 15;18(22):6284-95. doi: 10.1158/1078-0432.CCR-12-0896. Epub 2012 Oct 2.

28.

Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response.

Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, Benhamouda N, Cazes A, Le Pimpec-Barthes F, Gaugler B, Langlade-Demoyen P, Pivot X, Saas P, Maillère B, Tartour E, Borg C, Adotévi O.

Clin Cancer Res. 2012 May 15;18(10):2943-53. doi: 10.1158/1078-0432.CCR-11-3185. Epub 2012 Mar 8.

29.

Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy.

Godet Y, Desfrançois J, Vignard V, Schadendorf D, Khammari A, Dreno B, Jotereau F, Labarrière N.

Eur J Immunol. 2010 Jun;40(6):1786-94. doi: 10.1002/eji.200940132.

30.

Double positive CD4CD8 alphabeta T cells: a new tumor-reactive population in human melanomas.

Desfrançois J, Moreau-Aubry A, Vignard V, Godet Y, Khammari A, Dréno B, Jotereau F, Gervois N.

PLoS One. 2010 Jan 5;5(1):e8437. doi: 10.1371/journal.pone.0008437.

31.

An additional ORF on meloe cDNA encodes a new melanoma antigen, MELOE-2, recognized by melanoma-specific T cells in the HLA-A2 context.

Godet Y, Moreau-Aubry A, Mompelat D, Vignard V, Khammari A, Dreno B, Lang F, Jotereau F, Labarriere N.

Cancer Immunol Immunother. 2010 Mar;59(3):431-9. doi: 10.1007/s00262-009-0762-z.

PMID:
19730858
32.

Gap junction communication between autologous endothelial and tumor cells induce cross-recognition and elimination by specific CTL.

Benlalam H, Jalil A, Hasmim M, Pang B, Tamouza R, Mitterrand M, Godet Y, Lamerant N, Robert C, Avril MF, Neefjes J, Tursz T, Mami-Chouaib F, Kieda C, Chouaib S.

J Immunol. 2009 Mar 1;182(5):2654-64. doi: 10.4049/jimmunol.0800815.

33.

MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency.

Godet Y, Moreau-Aubry A, Guilloux Y, Vignard V, Khammari A, Dreno B, Jotereau F, Labarriere N.

J Exp Med. 2008 Oct 27;205(11):2673-82. doi: 10.1084/jem.20081356. Epub 2008 Oct 20.

34.

A new tyrosinase epitope recognized in the HLA-B*4002 context by CTL from melanoma patients.

Godet Y, Bonnin A, Guilloux Y, Vignard V, Schadendorf D, Dreno B, Jotereau F, Labarriere N.

Cancer Immunol Immunother. 2009 Feb;58(2):271-80. doi: 10.1007/s00262-008-0551-0. Epub 2008 Jul 9.

PMID:
18612636
35.

A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes.

Larrieu P, Renaud V, Godet Y, Jotereau F, Fonteneau JF.

Cancer Immunol Immunother. 2008 May;57(5):745-52. Epub 2007 Dec 21.

PMID:
18097665
36.

Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients.

Benlalam H, Vignard V, Khammari A, Bonnin A, Godet Y, Pandolfino MC, Jotereau F, Dreno B, Labarrière N.

Cancer Immunol Immunother. 2007 Apr;56(4):515-26. Epub 2006 Jul 28.

PMID:
16874485

Supplemental Content

Support Center